Altimmune posts Q4 net loss $23.2M; CMO to retire; pemvidutide MASH data on track

Altimmune, Inc.

2024-FY EPS reported -$1.34 revenue$20,000

Net loss Q4 2024 $23.2M ($0.33/share) vs $31.6M in Q4 2023 (incl $12.4M impairment); FY2024 net loss $95.1M ($1.34/share).
Cash, cash equivalents and short-term investments $131.9M at Dec 31, 2024.
CMO Dr. Scott Harris will retire effective Feb 28, 2026; company to search for successor.
Top-line data from Phase 2b IMPACT MASH trial expected Q2 2025; IND cleared for two additional indications with Phase 2 trials mid-2025.
Board adds Teri Lawver (ex-Dexcom, J&J) and Jerry Durso (ex-Intercept CEO, Sanofi).

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Harris

Chief Medical Officer

ALT · Altimmune, Inc.

Effective: 2026-02-28
Filed: February 27, 2025, 6:59 PM ET

On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Harris departed as Chief Medical Officer at Altimmune, Inc..

Action: retire
Role: Chief Medical Officer

Exact text from the filing

On February 24, 2025, the Company’s Chief Medical Officer, Dr. Scott Harris, provided the Company advance notice of his intention to retire from Altimmune as of February 28, 2026.

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-25-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.